Pediatric sHKTx has become an effective therapy for patients with combined cardiac and renal failure. Often, these patients develop human leukocyte antigen antibodies from their previous allografts and are therefore more difficult to re-transplant. We describe the largest case series of a predominantly sensitized pediatric sHKTx with emphasis on medical management and patient outcomes. Demographics, clinical characteristics, antibody, and biopsy data were retrospectively collected from University of California, Los Angeles database and correlated with short-and long-term patient and allograft outcomes of all sHKTx performed between 2002 and 2015. We identified seven pediatric patients who underwent sHKTx at our center. Mean age at time of sHKTx was 13.7 years and 85.7% were re-graft patients. 57.1% were sensitized with cPRA >50% and another 57.1% had preformed donor-specific antibody. Fiveyear renal allograft survival and patient survival was 85.7% for both end-points. The remaining six patients are all alive (mean follow-up 78.5 months) with good kidney and heart function. sHKTx in a population with increased immunological risk can be associated with good long-term outcomes and offers potential guidance to the pediatric transplant community where data are limited.
| INTRODUCTION
Pediatric sHKTx has become an effective treatment for patients with combined cardiac and renal failure. The first adult simultaneous heart and kidney transplant was described in 1978, 1 and the first pediatric sHKTx was performed in 1985. 2 In the past few decades, the landscape of ESRD has shifted dramatically transitioning from primary renal disease to secondary organ dysfunction or systemic illness necessitating the need for a kidney transplant. 3 The complex pathophysiologic interactions between the heart and the kidney are multifactorial and may lead to primary dysfunction of either organ. More commonly, patients with low cardiac output myocardial dysfunction develop renal failure secondary to nephrotoxic immunosuppressive medications, infections, and long-term ischemic renal hypoperfusion. 4, 5 Often, these patients develop HLA antibodies from their previous allografts and are therefore more difficult to re-transplant. [6] [7] [8] [9] [10] Currently, there is limited information in the literature regarding indications, preoperative patient characteristics, and outcomes of pediatric sHKTx. With the marked increase in sHKTx in the adult and pediatric population, including sensitized individuals, 11 there is a growing need to understand the optimal treatment for these patients. Therefore, we report the largest case series of a largely sensitized pediatric sHKTx cohort with emphasis on medical management and patient outcomes.
| METHODS

| Patient selection and evaluation
A total of 38 pediatric sHKTx have been performed in the United
States since 1988 based upon OPTN data as of April 30, 2017. 12 Seven (18.4%) of these patients were transplanted at Mattel
Children's Hospital at the UCLA. This is a single-center retrospective review of these seven patients who were identified at our follow-up data were collected from institutional databases and individual charts.
All seven patients had concomitant, chronic end-stage cardiac disease and renal failure. Donors were matched for ABO blood type compatibility. Our criteria for sHKTx included eligibility for heart transplant to treat progressive symptomatic heart failure failing medical therapy with unacceptable risk for cardiac death within 6 months and sustained GFR <50 mL/min/1.73 m 2 for more than 6 months. GFR was measured using radionuclide-labeled DTPA clearance corrected for body surface area prior to listing for sHKTx.
| Clinical protocols
Orthotopic heart transplantation was performed first per standard procedure. After stable hemodynamic status was established, kidney transplantation was performed within 24 hours following heart trans- MFI >1000 was considered positive for HLA-A, -B, -DR, -DQ, and ≥2000 for HLA-C and -DP. 14, 18 Non-adherence was defined as physician and/or clinic staff documentation of patient-reported MNA, undetectable drug levels, or missed appointments. 10 All patients with de novo DSA underwent renal and endomyocardial biopsies.
Non-HLA antibodies including ECXM and MICA were measured if clinically indicated. 19 Non-HLA antibodies have been associated with AMR and DGF. [20] [21] [22] Valganciclovir and sulfamethoxazole/trimethoprim prophylaxis was continued for 1 year post-transplantation. BK virus, cytomegalovirus, and Epstein-Barr virus PCR were monitored monthly for the first year, then quarterly thereafter. The eGFR is reported as a measure of renal function and was calculated using the updated Schwartz equation for all post-transplant measurements. 23 Serum creatinine concentration was measured using the enzymatic assay. DGF is defined by the requirement of renal replacement therapy within the first week post-kidney transplantation.
| RESULTS
The demographics are shown in Table 1 . Mean age at the time of sHKTx was 13.7 years with four males and three females. Three (42.9%) sHKTx patients required dialysis prior to transplant. Six (85.7%) were re-graft patients of either the kidney or the heart. Two (28.6%) patients had a primary kidney disease requiring transplantation (renal dysplasia and renal agenesis, respectively). Of the five remaining patients with secondary causes of renal failure, three (43%)
had CRS, while two (28.6%) had CNI toxicity. The two patients with CNI toxicity were switched to an mTOR inhibitor and low-dose CNIbased regimen with minimal improvement and eventually progressed to ESRD. The four cardiac re-graft patients all developed progressive cardiac allograft vasculopathy more than 10 years after their first heart transplant. Table 2 demonstrates the preoperative transplant characteristics of the cohort. All patients had significant heart and kidney failure prior to dual listing for sHKTx (Table 2) . Two patients had an eGFR ~45 mL/ min/1.73 m 2 and the remaining five patients had either CKD stage 4-5 24 or ESRD requiring dialysis. Ejection fraction of the left ventricle at the time of transplant ranged from 10% to 54% (Table 2) . While on the waiting list, four of seven patients required inotropic support. One patient required an AICD, while another patient required LVAD placement both 1 month before transplantation. Additionally, one patient required a dual chamber pacemaker 2 years prior to transplantation.
The average waiting time on the UNOS waiting list was 8.9 months (Table 2) .
Notably, there were no perioperative cardiac complications in the cohort. Renal complications including ATN or DGF developed in two (29%) patients (Table 2) . One patient required diuretics for ATN management. The other patient had DGF secondary to biopsyproven ATN and required CVVHD initiated on postoperative day (POD)#0 until his death on POD#30. This patient had VACTERL association (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities) and his first renal allograft failed after 10 years secondary to CNI toxicity and chronic urinary tract infections. This patient's heart failure was due to complex congenital heart disease with failed Fontan palliation that resulted in ascites and hepatic fibrosis. Because of early ATN, a renal sparing induction protocol was used. Daclizumab was selected in lieu of ATG due to concern for a recently treated invasive fungal infection. He eventually died from overwhelming sepsis and ARDS ( Table 3 ).
The postoperative transplant characteristics are shown in Table 3 .
The most recent outpatient blood pressure and degree of proteinuria measured from urinalysis are shown. As all of the patients except for patient 6 are >18 years, the guidelines from the AHA were used to categorize the hypertension. Renal pathology from the most recent protocol biopsy is shown. Patients 2 and 6 did not undergo protocol biopsies as they were transitioned to the adult kidney transplant program at their home medical center within 6 months after transplantation. Patient 7 expired within 1 month and thus protocol biopsies were not performed.
Overall, short-term outcomes including 1-year patient and sHKTx graft survival in the cohort were 85.7% and 85.7%, respectively.
Three-year patient and sHKTx graft survival continued to be consistent at 85.7% and 85.7%. The remaining six patients had considerable improvement in renal and cardiac function post-transplantation with good long-term allograft function (Figures 1 and 2 ). All are alive with adequate heart and kidney graft function at 2-14 years post-transplantation. In our cohort, the main indication for sHKTx was hypoperfusion to the kidney secondary to repeated episodes of sepsis and/or nephrotoxic medications from a previous heart transplant. This reflects the changing nature of simultaneous transplantation of combined endstage heart and kidney failure. VACTERL association and syndromes that encompass defects in both kidney and heart functions are no longer primary indications for sHKTx. Instead, advances in both immunosuppressive regimens and surgical techniques have led to improved post-transplant survival of patients with isolated kidney or heart transplant. Consequently, the population of patients requiring combined organ re-transplantation has increased, and these patients are more likely to be sensitized. Evaluating the management and associated outcomes of these high-risk patients is of critical importance.
Our short-and long-term outcomes were good despite poor kidney and heart function prior to transplant and the complexity of the recipients in comparison with sensitized pediatric cardiac patients.
Jacobs et al. 6 reported 30-day mortality of 25% for their cohort of highly sensitized cardiac transplant patients and Pollock-BarZiv et al. T A B L E 2 Pretransplant characteristics overwhelming sepsis. Daclizumab is a humanized monoclonal antibody against the interleukin-2 (IL-2) receptor that has been used successfully for induction immunosuppression in kidney transplantation with minimal side effects. 27 However, for cardiac transplantation, daclizumab has been associated with an increased risk of overwhelming infection leading to death, which is consistent with our experience. 28 These data were not published when the decision was made to use it in our patient. Thus, we recommend using ATG induction therapy for sHKTx.
Risk factors for morbidity and mortality have not been studied in pediatric sHKTx. We found that the use of daclizumab was the sole risk factor for mortality in pediatric sHKTx. Traditional risk factors associated with increased morbidity and mortality in adult sHKTx, such as dialysis and pretransplant need of a ventricular assist device, were not major factors in our pediatric cohort. By contrast, using UNOS data, Russo et al. 29 found that risk factors for diminished survival in adult sHKTx included patients >65 years at the time of transplant, peripheral vascular disease, non-ischemic etiology of heart failure, dialysis dependence at the time of transplantation, and those who required using a ventricular assist device as a bridge to transplantation. However, Russo et al. did not address the issue of sensitization. We found that neither cPRA >50% nor low level of preformed antibody was associated with allograft loss or death. Additionally, our patient with multiple recurrent kidney allograft rejection episodes from MNA has not had any episodes of cardiac rejection. This possible "protective effect" of a single allograft in comparison with multiorgan co-transplants of liver, kidney, and heart allografts has been previously demonstrated. 30 Our study is consistent with previous studies in the adult population and supports the idea that sHKTx patients have decreased long-term morbidity, including decreased number of heart rejection episodes, and decreased development of cardiac allograft vasculopathy, possibly through immunological tolerance. [31] [32] [33] [34] In the pediatric population, the rate of development of ESRD following isolated pediatric heart transplantation is between 1% and 3%. 35 39 This would suggest that for high-risk children with chronic failing heart and kidneys, who are predominantly sensitized, such as in our cohort, an eGFR cutoff of <50 mL/min/1.73 m 2 may be reasonable. Schaffer et al. 40 in 2013 found that 5-year post-transplant survival was improved in sHKTx adult patients vs isolated heart transplant recipients, regardless of dialysis status. Furthermore, preemptive kidney transplantation has been associated with improved long-term patient and renal allograft survival. [41] [42] [43] However, native kidney function must be optimized prior to transplant given the current shortage of organs as patient with CKD stage 3 can be maintained with stable renal function for several years. CNI sparing regimens should be instituted prior to significant eGFR decline. This is highlighted by the fact that our two patients with moderate/severe CKD stage 3 progressed to ESRD despite conversion to a CNI minimization regimen. Some providers might advocate staging heart and kidney transplantation by offering isolated heart transplant recipients to stable CKD stage 3 patients and only proceeding with kidney transplantation for patients with CKD stage 4 and/or ESRD. Pediatric patients with kidney after heart transplantation have good clinical outcomes, with a >90% survival rate at 1 and 5 years. 44 In conclusion, successful patient and allograft outcomes were attained with frequent monitoring and immediate intervention in our case series of predominantly sensitized patients. We recognize the limitations of our study including retrospective nature, varying induction therapies, and small sample size. Nonetheless, given the scarcity of data in the literature, this single institution experience with highrisk pediatric patients can offer potential guidance regarding indication, management, and long-term outcomes for sHKTx.
